Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Haemonetics (HAE) Equity Ratio (2016 - 2025)

Haemonetics has reported Equity Ratio over the past 16 years, most recently at 0.37 for Q4 2025.

  • For Q4 2025, Equity Ratio rose 2.14% year-over-year to 0.37; the TTM value through Dec 2025 reached 0.37, up 2.14%, while the annual FY2025 figure was 0.33, 23.4% down from the prior year.
  • Equity Ratio for Q4 2025 was 0.37 at Haemonetics, up from 0.35 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.44 in Q3 2023 and troughed at 0.33 in Q1 2025.
  • A 5-year average of 0.39 and a median of 0.39 in 2022 define the central range for Equity Ratio.
  • Biggest five-year swings in Equity Ratio: decreased 26.87% in 2022 and later rose 13.68% in 2023.
  • Year by year, Equity Ratio stood at 0.39 in 2021, then increased by 6.56% to 0.41 in 2022, then grew by 3.76% to 0.43 in 2023, then fell by 16.43% to 0.36 in 2024, then grew by 2.14% to 0.37 in 2025.
  • Business Quant data shows Equity Ratio for HAE at 0.37 in Q4 2025, 0.35 in Q3 2025, and 0.36 in Q2 2025.